Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; 22 of the 28 sources its claims cite were checked for support.

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction

Open access
Small, Aeron M., Yang, Ta-Yu, Itoh, Shinsuke, Thériault, Sébastien, Dufresne, Line, Kurosawa, Ryo, Komuro, Issei, Matsuda, Koichi, Vy, Ha My T., Farber-Eger, Eric H., Shaffer, Lauren Lee, Boulier, Kristin M., Corey, Kristin M., Ramaker, Megan E., Laporte, Fabien, Schott, Jean-Jacques, Le Scouarnec, Solena, Singh, Sasha A., Sonawane, Abhijeet R., Smith, Harry A., Rafaels, Nicholas, Colorado Center for Personalized Medicine, Ghouse, Jonas, Raja, Anna A., Ostrowski, Sisse R., Sørensen, Erik, Mikkelsen, Christina, Pedersen, Ole B., Erikstrup, Christian, Ullum, Henrik, DBDS Genomic Consortium, Sveinbjornsson, Gardar, Gudbjartsson, Daniel F., Abner, Erik, Estonian Biobank Research Team, Lee, Jiwoo, Ganna, Andrea, Nowak-Göttl, Ulrike, Finer, Sarah, Genes & Health Research Team, van Heel, David A., Schumacher, Johannes, Maj, Carlo, Al-Kassou, Baravan, Nickenig, Georg, Trenkwalder, Teresa, Dreβen, Martina, Krane, Markus, Nöthen, Markus M., Moksnes, Marta R., Brumpton, Ben M., Knight, Stacey, Knowlton, Kirk U., Nadauld, Lincoln, Debiec, Radek, Musameh, Muntaser D., Braund, Peter S., Nelson, Christopher P., Czuba, Tomasz, Melander, Olle, Selvaraj, Margaret Sunitha, Koyama, Satoshi, Bhukar, Rohan, Ruan, Yunfeng, Ljungberg, Johan, Damrauer, Scott M., Levin, Michael G., Franke, Andre, Berger, Klaus, Ruff, Christian T., Melloni, Giorgio E. M., Kamanu, Frederick K., Ito, Kaoru, Do, Ron, Loos, Ruth J. F., Schunkert, Heribert, Wells, Quinn S., Shah, Svati H., Le Tourneau, Thierry, Messika-Zeitoun, David, Gignoux, Christopher, Bundgaard, Henning, Larsson, Susanna C., Michaëlsson, Karl, Holm, Hilma, Helgadottir, Anna, Esko, Tonu, van Heel, David A., Mathieu, Patrick, Samani, Nilesh J., Smith, J. Gustav, Söderberg, Stefan, Rader, Daniel J., Marston, Nicholas A., Sabatine, Marc S., Pasaniuc, Bogdan, Cho, Kelly, Wilson, Peter W. F., O’Donnell, Christopher J., Stefansson, Kari, Bossé, Yohan, Aikawa, Elena, Engert, James C., Peloso, Gina M., Natarajan, Pradeep, Thanassoulis, George · 2026 · Nature Genetics

Abstract

Aortic stenosis (AS) is a common valvular heart disease and has no pharmacological therapies. We performed a multi-ancestry genome-wide association meta-analysis of 86,864 AS cases among 2,853,408 individuals, discovering 241 autosomal independent risk loci and 3 X chromosome risk loci. We additionally performed sex-stratified and ancestry-stratified genome-wide association studies (GWASs), identifying an additional 5 sex-specific risk loci, 11 risk loci in European ancestry individuals and 1 risk locus in African ancestry individuals. We also performed a transcriptome-wide association study using expression quantitative trait loci from human aortic valves, discovering 54 new genes for which genetically predicted expression influences the risk of AS. We then generated a new polygenic risk score for AS. Finally, we performed gene silencing experiments targeting biologically relevant genes identified by our GWAS. Silencing of CMKLR1 and LTBP4 in human valvular interstitial cells substantially decreased mineralization, implicating a role for polyunsaturated fatty acids and transforming growth factor β signaling in AS.

Overview

CoChat Summary

TL;DR

This multi-ancestry GWAS and transcriptomic study of aortic stenosis identified 261 independent risk loci and 54 new TWAS genes, and generated an AS polygenic risk score that outperformed a prior score. Functional silencing implicated CMKLR1 and LTBP4 in valvular calcification.

Key findings

  • In 86,864 AS cases among 2,853,408 individuals, the multi-ancestry GWAS found 241 autosomal and 3 X chromosome independent risk loci; combined analyses yielded 261 independent lead variants, with 223 reported as new in the Results (the Discussion states 225 new).
  • TWAS using human aortic valve eQTLs identified 192 Bonferroni-significant genes, 66 with significant colocalization, and 54 of 66 were new compared with prior AS TWAS; 8 genes had an expression specificity score >0.1.
  • The best AS PRS used LDpred2 with proportion of causal SNPs 0.056, heritability 1.4, and sparsity enabled; it had Nagelkerke r² = 0.007 in MGBB and validated with adjusted HR = 1.92 (1.85–1.99) per 1 s.d. in UKB and HR = 1.80 (1.60–2.04) in TIMI trials.
  • Silencing CMKLR1 and LTBP4 in human valvular interstitial cells significantly reduced calcification (CMKLR1 mean difference = −0.19, P = 0.028; LTBP4 mean difference = −0.31, P = 0.049), whereas silencing CLCA2, CERS2, or CEP120 did not substantially suppress calcification.

Methods

  • Multi-ancestry GWAS meta-analysis of 30 studies in the International Aortic Valve Genetics Consortium, including autosomes and X chromosome, with ancestry-stratified and sex-stratified analyses; fixed-effects inverse-variance weighted meta-analysis was used, with genome-wide significance at P < 5 × 10⁻⁸.
  • TWAS used human aortic valve transcriptomes and eQTLs from 484 individuals in QUEBEC-CAVS, analyzed with S-PrediXcan/MetaXcan and COLOC; Bonferroni threshold was P < 4.73 × 10⁻⁶ and colocalization was defined as PP4 > 0.75.
  • PRS development used LDpred2 and PRS-CS, with validation in MGBB, UKB, UCLA ATLAS, and six TIMI trials; functional work used siRNA silencing of five prioritized genes in human VICs, Alizarin red calcification assays, and immunofluorescence in human aortic valves.

Limitations

  • The paper states that AS was defined using a claims-based definition validated in MVP with positive predictive value 0.78 and negative predictive value 0.99; ICD-9 code 424.1 captures both AS and aortic regurgitation, so mixed valve disease may be included.
  • The paper states the population is predominantly of European genetic ancestry, limiting generalizability; the largest contributor was MVP, a >95% male population, skewing cases to majority male and giving better power for discovery in men than women, with possible inclusion of a small number of bicuspid AV cases.
  • Evident from the text: non-European ancestry analyses were underpowered, with no genome-wide significant variants in Hispanic, East Asian, or South Asian ancestries and only one African ancestry locus; PRS performance in MGBB was modest (Nagelkerke r² = 0.007), and non-European ORs were lower (1.23–1.38) than European HRs.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41588-025-02417-6

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Circos plot of multi-ancestry AS GWAS. Circular Manhattan plot of our multi-ancestry AS GWAS results in both autosomes and the X chromosome. Genome-wide significance (P = 5 × 10−8), indicated by the inner red circle. Prioritized genes are highlighted at chromosomal position at outer circle, new loci are red and replicated loci are black.
Fig. 1 Circos plot of multi-ancestry AS GWAS. Circular Manhattan plot of our multi-ancestry AS GWAS results in both autosomes and the X chromosome. Genome-wide significance (P = 5 × 10−8), indicated by the inner red circle. Prioritized genes are highlighted at chromosomal position at outer circle, new loci are red and replicated loci are black.CC BY · PubMed Central
Fig. 2 Trumpet plot of lead variants in multi-ancestry as well as ancestry-stratified and sex-stratified AS GWASs. Trumpet plot representing effect size and effect allele frequencies for lead variants. Lead variants are colored green if identified in multi-ancestry, gray if a prior AS risk locus, red if specific to African ancestry GWAS, blue if specific to European ancestry and yellow if specific to male sex GWAS. Variants with high effect sizes are labeled by the nearest gene.
Fig. 2 Trumpet plot of lead variants in multi-ancestry as well as ancestry-stratified and sex-stratified AS GWASs. Trumpet plot representing effect size and effect allele frequencies for lead variants. Lead variants are colored green if identified in multi-ancestry, gray if a prior AS risk locus, red if specific to African ancestry GWAS, blue if specific to European ancestry and yellow if specific to male sex GWAS. Variants with high effect sizes are labeled by the nearest gene.CC BY · PubMed Central
Fig. 3 Manhattan plot of TWAS using human AV eQTLs. Manhattan plot of TWAS using European AS GWAS summary statistics and expression eQTLs data from human AVs. Z score represents magnitude and direction of association between genetically determined AV gene expression and AS risk. Genes in red are new TWAS associations. Only the most associated gene is labeled when multiple genes were identified at the same locus.
Fig. 3 Manhattan plot of TWAS using human AV eQTLs. Manhattan plot of TWAS using European AS GWAS summary statistics and expression eQTLs data from human AVs. Z score represents magnitude and direction of association between genetically determined AV gene expression and AS risk. Genes in red are new TWAS associations. Only the most associated gene is labeled when multiple genes were identified at the same locus.CC BY · PubMed Central
Fig. 4 Overview of causal gene prioritization. Schematic depicting variants with a gene prioritized by at least three methods. Green represents multi-ancestry GWAS; blue represents European genetic ancestry. A total of 154 multi-ancestry unique lead variants, 8 European genetic unique ancestry lead variants, 5 male sex unique lead variants, 1 African genetic ancestry unique lead variant and 3 X chromosome unique lead variants with less than three supportive methods are not shown.
Fig. 4 Overview of causal gene prioritization. Schematic depicting variants with a gene prioritized by at least three methods. Green represents multi-ancestry GWAS; blue represents European genetic ancestry. A total of 154 multi-ancestry unique lead variants, 8 European genetic unique ancestry lead variants, 5 male sex unique lead variants, 1 African genetic ancestry unique lead variant and 3 X chromosome unique lead variants with less than three supportive methods are not shown.CC BY · PubMed Central
Fig. 5 Performance of AS PRS in European genetic ancestry individuals from the UK Biobank, TIMI trials and UCLA ATLAS. a, Forest plot of AS PRS validation in the UK Biobank, TIMI clinical trials and UCLA ATLAS. b, Forest plot comparing the HR for categories of genetic risk and individual risk factors in the UKB. Forest plot in a demonstrating HRs/ORs and 95% CI per 1 s.d. PRS for the new AS PRS compared to a previously published PRS in the UK Biobank (n = 446,895), TIMI trials (n = 59,866) and the UCLA ATLAS (n = 34,024), as well as a meta-analysis (Meta) of the UK Biobank and TIMI trial results. All analyses are adjusted for age, sex, five principal components and clinical risk factors including T2D, HTN, CAD, HLD, elevated BMI, current smoking and renal failure. Forest plot in b demonstrating HRs for genetic risk categories and individual risk factors with AS in the UKB (n = 446,895). eGFR, estimated glomerular filtration rate; CI, confidence interval; BMI, body mass index.
Fig. 5 Performance of AS PRS in European genetic ancestry individuals from the UK Biobank, TIMI trials and UCLA ATLAS. a, Forest plot of AS PRS validation in the UK Biobank, TIMI clinical trials and UCLA ATLAS. b, Forest plot comparing the HR for categories of genetic risk and individual risk factors in the UKB. Forest plot in a demonstrating HRs/ORs and 95% CI per 1 s.d. PRS for the new AS PRS compared to a previously published PRS in the UK Biobank (n = 446,895), TIMI trials (n = 59,866) and the UCLA ATLAS (n = 34,024), as well as a meta-analysis (Meta) of the UK Biobank and TIMI trial results. All analyses are adjusted for age, sex, five principal components and clinical risk factors including T2D, HTN, CAD, HLD, elevated BMI, current smoking and renal failure. Forest plot in b demonstrating HRs for genetic risk categories and individual risk factors with AS in the UKB (n = 446,895). eGFR, estimated glomerular filtration rate; CI, confidence interval; BMI, body mass index.CC BY · PubMed Central
Fig. 6 Suppression of calcification in human VICs cultured in OM by silencing of LTBP4 and CMKLR1, and their colocalization with calcification in human AV. a, Alizarin red staining identifies calcification in human VICs (example with two of eight donors). Silencing of LTBP4 and CMKLR1 significantly suppressed calcification in human VICs cultured in OM. Total n = 11 VIC donors. b, Validation of silencing of LTBP4 and CMKLR1 by siRNA transfection; qPCR. Silencing of LTBP4 and CMKLR1 significantly suppressed their gene expression levels in human VICs (mean ± s.d., n = 8; P < 0.05, two-tailed paired t test). Box plots show the distribution from minimum to maximum values. The box represents the interquartile range (25th to 75th percentiles), with the line inside the box indicating the median. Whiskers extend to the minimum and maximum data points. c, Immunofluorescence staining of LTBP4 and CMKLR1 showed colocalization with calcific nodules and calcifying cells (OsteoSense680; yellow arrows) in human AV (n = 3 donors). LTBP4 expression in smooth muscle-like cells (orange arrow). CMKLR1 is colocalized with microvessels in human AV (green arrow, inset). Scale bars, 100 µm.
Fig. 6 Suppression of calcification in human VICs cultured in OM by silencing of LTBP4 and CMKLR1, and their colocalization with calcification in human AV. a, Alizarin red staining identifies calcification in human VICs (example with two of eight donors). Silencing of LTBP4 and CMKLR1 significantly suppressed calcification in human VICs cultured in OM. Total n = 11 VIC donors. b, Validation of silencing of LTBP4 and CMKLR1 by siRNA transfection; qPCR. Silencing of LTBP4 and CMKLR1 significantly suppressed their gene expression levels in human VICs (mean ± s.d., n = 8; P < 0.05, two-tailed paired t test). Box plots show the distribution from minimum to maximum values. The box represents the interquartile range (25th to 75th percentiles), with the line inside the box indicating the median. Whiskers extend to the minimum and maximum data points. c, Immunofluorescence staining of LTBP4 and CMKLR1 showed colocalization with calcific nodules and calcifying cells (OsteoSense680; yellow arrows) in human AV (n = 3 donors). LTBP4 expression in smooth muscle-like cells (orange arrow). CMKLR1 is colocalized with microvessels in human AV (green arrow, inset). Scale bars, 100 µm.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 1 Not valid · 2 Not checked · 97 Own results and interpretations

60 more claims · 3 with their cited sources checked

Create a free account to see all 114 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 70 references

Cited by

See all 18

Metadata

Authors
Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., Shaffer, L. L., Boulier, K. M., Corey, K. M., Ramaker, M. E., Laporte, F., Schott, J.-J., Le Scouarnec, S., Singh, S. A., Sonawane, A. R., Smith, H. A., Rafaels, N., Colorado Center for Personalized Medicine, Ghouse, J., Raja, A. A., Ostrowski, S. R., Sørensen, E., Mikkelsen, C., Pedersen, O. B., Erikstrup, C., Ullum, H., DBDS Genomic Consortium, Sveinbjornsson, G., Gudbjartsson, D. F., Abner, E., Estonian Biobank Research Team, Lee, J., Ganna, A., Nowak-Göttl, U., Finer, S., Genes & Health Research Team, van Heel, D. A., Schumacher, J., Maj, C., Al-Kassou, B., Nickenig, G., Trenkwalder, T., Dreβen, M., Krane, M., Nöthen, M. M., Moksnes, M. R., Brumpton, B. M., Knight, S., Knowlton, K. U., Nadauld, L., Debiec, R., Musameh, M. D., Braund, P. S., Nelson, C. P., Czuba, T., Melander, O., Selvaraj, M. S., Koyama, S., Bhukar, R., Ruan, Y., Ljungberg, J., Damrauer, S. M., Levin, M. G., Franke, A., Berger, K., Ruff, C. T., Melloni, G. E. M., Kamanu, F. K., Ito, K., Do, R., Loos, R. J. F., Schunkert, H., Wells, Q. S., Shah, S. H., Le Tourneau, T., Messika-Zeitoun, D., Gignoux, C., Bundgaard, H., Larsson, S. C., Michaëlsson, K., Holm, H., Helgadottir, A., Esko, T., van Heel, D. A., Mathieu, P., Samani, N. J., Smith, J. G., Söderberg, S., Rader, D. J., Marston, N. A., Sabatine, M. S., Pasaniuc, B., Cho, K., Wilson, P. W. F., O’Donnell, C. J., Stefansson, K., Bossé, Y., Aikawa, E., Engert, J. C., Peloso, G. M., Natarajan, P., & Thanassoulis, G.
Affiliations
  • Broad Institute (US)
  • Kyoto University (JP)
  • Brigham and Women's Hospital (US)
  • Institut universitaire de cardiologie et de pneumologie de Québec (CA)
  • McGill University Health Centre (CA)
  • RIKEN Center for Integrative Medical Sciences (JP)
  • The University of Tokyo (JP)
  • Institute of Medical Science, The University of Tokyo (JP)
  • Icahn School of Medicine at Mount Sinai (US)
  • Vanderbilt University Medical Center (US)
  • Ronald Reagan UCLA Medical Center (US)
  • Duke University (US)
  • Centre National de la Recherche Scientifique (FR)
  • University of Colorado Anschutz (US)
  • Copenhagen University Hospital (DK)
  • University of Copenhagen (DK)
  • Aarhus University Hospital (DK)
  • Statens Serum Institut (DK)
  • deCODE Genetics (Iceland) (IS)
  • University of Tartu (EE)
  • University of Helsinki (FI)
  • Queen Mary University of London (GB)
  • University of Bonn (DE)
  • Philipps University of Marburg (DE)
  • German Centre for Cardiovascular Research (DE)
  • Yale University (US)
  • Norwegian University of Science and Technology (NO)
  • Intermountain Healthcare (US)
  • University of Leicester (GB)
  • Sahlgrenska University Hospital (SE)
  • Lund University (SE)
  • Massachusetts General Hospital (US)
  • Umeå University (SE)
  • Philadelphia VA Medical Center (US)
  • University of Pennsylvania (US)
  • University of Münster (DE)
  • Chiba University (JP)
  • Uppsala University (SE)
  • Atlanta VA Medical Center (US)
  • Boston University (US)
Corresponding author
  • Natarajan, Pradeep
  • Thanassoulis, George
Venue
Nature Genetics
Published
2025-12-19
Volume
58
Issue
1
Pages
57-66
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W4417492474
Cited by
18
References
70
Citations by year
2026: 18
FWCI
2.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Genetics (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Diva portal (Dalarna University Library) (submittedVersion, other-oa)
  • HAL (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
  • Gouvernement du Canada | Canadian Institutes of Health Research
  • Fonds de Recherche du Québec - Santé
  • Heart and Stroke Foundation of Canada
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Mapping and Diversity in Plants and Animals
Keywords
aortic stenosis, valvular heart disease, genetic susceptibility loci, transcriptome-wide association study, expression quantitative trait loci, polygenic risk score, CMKLR1, LTBP4, valvular interstitial cells, calcification, polyunsaturated fatty acids, TGF-beta signaling, therapeutic target discovery, disease prediction
MeSH terms
Aortic Valve Stenosis, Female, Humans, Male, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Gene Expression Profiling, Genomics, Quantitative Trait Loci, White People, Genome-Wide Association Study, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction. https://app.cochat.ai/papers/10.1038/s41588-025-02417-6
The paper
Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., Shaffer, L. L., Boulier, K. M., Corey, K. M., Ramaker, M. E., Laporte, F., Schott, J.-J., Le Scouarnec, S., Singh, S. A., Sonawane, A. R., . . . Thanassoulis, G. (2026). Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction. Nature Genetics. https://doi.org/10.1038/s41588-025-02417-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.